Quality over quantity: biopsy-anchored CT radiogenomics models outperform all-lesion training in a multi-tumour cohort despite a smaller sample size
Clinical Scorecard: Prioritizing Quality: Biopsy-Based CT Radiogenomics Models Surpass All-Lesion Training in a Multi-Tumor Analysis Despite Reduced Sample Size
At a Glance
Category Detail
Condition Solid Tumors with EGFR Mutations Key Mechanisms Intra- and inter-tumoral heterogeneity affecting mutation concordance Target Population Patients with solid tumors undergoing biopsy for next-generation sequencing Care Setting Oncology, specifically within institutions conducting precision oncology
Key Highlights
Single tissue samples may not represent the genomic complexity of malignancies. EGFR mutations show significant discordance rates, especially in treatment-exposed patients. Radiogenomics can non-invasively capture tumor biology across visible disease. Training models on biopsy-confirmed lesions improves generalizability. The study establishes a framework for integrating radiogenomics with tissue testing. Guideline-Based Recommendations
Diagnosis
Utilize comprehensive imaging to assess tumor heterogeneity. Confirm EGFR mutation status through biopsy and consider lesion-specific testing. Management
Incorporate radiogenomic data to guide targeted therapy decisions. Consider lesion-level molecular heterogeneity when planning treatment. Monitoring & Follow-up
Regularly assess imaging features to track tumor response and evolution. Monitor for discordance in mutation status across lesions. Risks
Assuming molecular homogeneity can lead to misinformed treatment decisions. Label noise from biopsy-derived mutation status may affect model accuracy. Patient & Prescribing Data
Patients with solid tumors, particularly those with EGFR mutations.
Targeted therapies should be informed by comprehensive molecular profiling.
Clinical Best Practices
Use biopsy-confirmed lesions for training radiogenomic models. Integrate imaging and genomic data to enhance precision oncology outcomes. Adhere to CLEAR criteria for radiomics research reporting. Related Resources & Content
